PATENT CLAIM ANALYSIS

Application Number: 16028112
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "101000"]

Abstract:
The present invention includes composition and methods for inhibiting or decreasing impaired systolic ejection fraction associated with cardiotoxic therapeutic treatment in a subject receiving a cardiotoxic chemotherapeutic agent causing impaired systolic ejection fraction comprising: identifying a subject in need of cardioprotection from the therapeutic treatment; and delivering an effective amount of a phospholipid or derivatives thereof that is cardioprotective to the heart of the subject thereby inhibiting or decreasing impaired systolic ejection fraction associated with administration of the cardiotoxic chemotherapeutic treatment to the subject.

Claim (Index 15):
The method of  claim 10 , wherein the cardiotoxic therapeutic treatment is a radiotherapeutic agent is selected from the group consisting of  47 Sc,  64 Cu,  67 Cu,  89 Sr,  86 Y,  87 Y,  90 Y,  105 Rh,  111 Ag,  111 In,  117 Sn,  149 Pm,  153 Sm,  166 Ho,  177 Lu,  186 Re,  188 Re,  211 At,  212 Bi, and combinations thereof.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 95.0
- Lexical Diversity: 1.70588
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15297901', '15347381', '15788683', '14729940', '14844475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7939814796840283
- 35 USC 102 Novelty (BERT): 0.5143582487925492
- Combined Prediction Score: 0.7660191565948804
- Mean Citation Score: 261.440028
- Max Citation Score: 279.11548
- Similarity Product: 175.8498382517433

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test